Northwire Canada EditionThursday, October 15, 2026
Northwire
⌕
GOLD 4107.90 −1.7% SILVER 55.88 −6.1% COPPER 6.62 −1.6% OIL 95.09 +1.0% PALLADIUM 1096.50 −2.7% CIA 2.64 −0.4% BTO 7.09 −4.3% MCI 0.155 +0.0% CAN 0.065 +0.0% BLDS 0.335 +8.1% SAO 0.050 +0.0% SF 0.315 +0.0% BEA 0.055 −15.4% BMM 3.90 +11.1% AUGC 0.295 −13.2% MFG 3.34 −3.8% CDE 21.33 −7.7% CYG 0.160 −5.9% RSMX 0.100 −4.8% TUF 0.830 −5.7% GPG 0.285 −3.4% GOLD 4107.90 −1.7% SILVER 55.88 −6.1% COPPER 6.62 −1.6% OIL 95.09 +1.0% PALLADIUM 1096.50 −2.7% CIA 2.64 −0.4% BTO 7.09 −4.3% MCI 0.155 +0.0% CAN 0.065 +0.0% BLDS 0.335 +8.1% SAO 0.050 +0.0% SF 0.315 +0.0% BEA 0.055 −15.4% BMM 3.90 +11.1% AUGC 0.295 −13.2% MFG 3.34 −3.8% CDE 21.33 −7.7% CYG 0.160 −5.9% RSMX 0.100 −4.8% TUF 0.830 −5.7% GPG 0.285 −3.4%
M&A / Property Routine +

PharmaCorp Completes Acquisition of Pharmacy Files in Western Canada

PharmaCorp Rx Inc.

Executive Summary
  • PharmaCorp Rx Inc. completed the acquisition of pharmacy files, patient records, and operational data in Western Canada for a purchase price of $300,000.
  • The transaction was funded entirely with cash on hand; no external financing or finder's fees were required.
  • Assets will be integrated into an existing PharmaChoice-bannered pharmacy to enhance operational efficiency and continuity of care.
  • This follows a non-binding Letter of Intent (LOI) announced in December 2025 for approximately $350,000.
  • The acquisition excludes the target's corporate entity, fixtures, or other operating assets.
Material Impact
  • Materiality: Low to Moderate. While positive for execution, the $300,000 purchase price is negligible relative to Fiscal Year 2025 revenue of $20.9 million and cash position of $25.9 million.
  • Expectations: The deal was anticipated following the December 2025 LOI; therefore, it does not contain unexpected market-moving information.
  • Context: This news is overshadowed by the April 30, 2026 announcement to acquire eight pharmacies for $24.2 million. The May 1 filing confirms smaller pipeline progress but does not alter the primary growth thesis established yesterday.
  • Financial Impact: Minimal immediate impact on revenue or earnings; primarily operational integration benefit.
PCRX · Price
Company Overview
  • Business Model: Retail pharmacy operator under the PharmaChoice Canada banner, focusing on national consolidation through M&A.
  • Flagship Project: Expansion of the pharmacy network across Western and Eastern Canada via acquisition of independent pharmacies and pharmacy files.
  • Growth Strategy: Acquiring existing locations to scale revenue quickly while maintaining local management continuity.
  • Operational Focus: Integration of patient records and operational data to improve efficiency without disrupting care continuity.
Read the original news release →

More from PharmaCorp Rx Inc.